The strong beat and raised guidance, particularly the accelerating Diagnostics segment (+11% organic), signal improving end-market demand. The China IDX divestiture simplifies the portfolio and removes a ~6% revenue headwind. Traders should watch for potential multiple expansion as the market prices in the raised guidance and margin recovery. The Life Sciences segment decline (-3% organic) is a modest offset but is being outpaced by Diagnostics strength.
Price Chart
Executive Summary
Revvity reported Q2 2026 adjusted EPS of $1.41, a 19.5% beat vs the $1.22 consensus, on revenue of $730M (above $703.2M consensus). The company raised full-year 2026 pro forma adjusted EPS guidance to $5.30-$5.40 and revenue guidance to $2.83-$2.86B, citing strong Diagnostics segment growth (+11% pro forma organic) and tariff refunds. The filing also confirms a definitive agreement to divest the China Immunodiagnostics business for up to $200M, expected to close by end of 2027. The combination of a significant earnings beat, raised guidance, and portfolio simplification is a clear positive catalyst.
Key Financial Metrics
Key Facts
- Adjusted EPS from continuing operations of $1.41 vs consensus $1.22 (beat by +15.9%)
- Revenue of $730M vs consensus $703.2M (beat by +3.8%)
- Raised FY2026 guidance: pro forma adjusted EPS to $5.30-$5.40 (from $5.20-$5.30) and revenue to $2.83-$2.86B (from $2.81-$2.84B)
- Diagnostics segment pro forma organic revenue grew 11% YoY; Life Sciences pro forma organic revenue declined 3%
- Entered definitive agreement to divest China Immunodiagnostics business for up to $200M, expected to close by end of 2027
- Adjusted operating margin expanded to 28.9% from 26.6% YoY, boosted by $16M in tariff refunds
- Operating cash flow from continuing operations was $191.9M in Q2, up from $134.3M a year ago
Financial Impact
EPS beat of $0.19 (+15.9%) on consensus of $1.22; revenue beat of ~$27M (+3.8%) on consensus of $703.2M; FY guidance raised by $0.10 on EPS and $20M on revenue at midpoint
Risk Factors
- Life Sciences segment organic revenue declined 3% YoY, indicating ongoing weakness in that end-market
- Q2 adjusted EPS includes ~$0.11 from tariff refunds, which may not recur
- China IDX divestiture closing by end of 2027 is subject to regulatory approvals and could be delayed or modified
- FY2026 guidance is on a pro forma basis excluding China IDX, creating a comparison complexity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000031791-26-000022 |
| Document: q22026proformafinancialsta.htm | 0000031791-26-000022 |
| Document: pki-20260804.htm | 0000031791-26-000022 |
| Document: 0000031791-26-000022-index-headers.html | 0000031791-26-000022 |
| Document: 0000031791-26-000022-index.html | 0000031791-26-000022 |
| Document: 0000031791-26-000022.txt | 0000031791-26-000022 |
| 8-K Data (Synthetic) | 0000031791-26-000022 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 8w ago | 8-K | $111.39 $126.59 | ▲ +13.65% | ▲ +14.88% | $151.53 (+36.04%) |
May 5, 2026 21w ago | 8-K | $92.30 $100.39 | ▲ +8.76% | ▲ +3.81% | $151.53 (+64.17%) |
Mar 16, 2026 28w ago | DEFA14A | $86.41 $93.44 | ▲ +8.13% | ▲ +4.35% | $151.53 (+75.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access